Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Materials for an American congress in Canada
-
Hi! An American congress for HCPs is taking place in Canada in 2024 and there will be attendees from both the US and Canada. We are developing a website and a leave-behind for this congress on behalf of an American pharmaceutical company with an investigational agent that is not currently approved for use in any country. These materials will be completely unbranded and will only discuss the disease and the current class of therapies; we would also like to discuss the burden of medication, challenges with adherence, and low/slow response rates to the class of therapies that are currently available for this disease. The website will be available after the congress, so the Canadian attendees would presumably be able to access this site once the congress is over.
Do these materials fall under Health Canada purview? If so, would this website and leave-behind need to be submitted to PAAB?
-
Hi! An American congress for HCPs is taking place in Canada in 2024 and there will be attendees from both the US and Canada. We are developing a website and a leave-behind for this congress on behalf of an American pharmaceutical company with an investigational agent that is not currently approved for use in any country. These materials will be completely unbranded and will only discuss the disease and the current class of therapies; we would also like to discuss the burden of medication, challenges with adherence, and low/slow response rates to the class of therapies that are currently available for this disease. The website will be available after the congress, so the Canadian attendees would presumably be able to access this site once the congress is over.
Do these materials fall under Health Canada purview? If so, would this website and leave-behind need to be submitted to PAAB?
Happy Friday @vincent
The nature of this question is complex and there is more information that would be required to answer it. We would suggest submitting an opinion where all the details required to make the assessment can be provided.
